1. Introduction
Covid-19 is an emerging viral infectious disease caused by the novel coronavirus 2 of the severe acute respiratory system, SARS-CoV 2. The WHO learned of its existence on December 31, 2020 when an outbreak of “viral pneumonia” cases was notified in the city of Wuhan, Hubei province in China [
1]. The 30th January, the WHO declared the outbreak a public health emergency of international concern and then a pandemic the 11th march 2020 [
2]. On February 11, the WHO officially names the disease “coronavirus disease (Covid-19)” after germ isolation and molecular characterization on January 07, 2020 [
2,
3].
As of 27 November 2022, the world has recorded 637 million confirmed cases and 6.6 million deaths globally [
4]. In general, the United States of America (USA) represents so far the most affected country in the world with above 98,972,375 cases [
4]. In Africa, COVID has affected all 47 African Region countries with 8.887.814 cumulative cases, which represented around two percent of the infections around the world [
5]. South Africa is the most drastically affected country, with more than 3.6 million infections, followed by Cameroon with 123 993 cases of COVID-19, of which 1965 died and above 2,960 were cured [
5].
In view of the rapid transmission capacity of this disease, unspecified interventions such as social distancing, barrier measures and quarantine can slow the spread of the virus and flatten the epidemic curve; however, the Covid-19 epidemic will only end if herd immunity is well established among the population, which is usually acquired through infection or vaccination. Although there have been barrier measures since the start of the pandemic, the morbidity rate is still increasing [
6]. It is therefore urgent to find other effective strategies to overcome this disease. According to WHO, the Covid-19 vaccine remains the best weapon to effectively fight the pandemic. As of 23 December 2021, the WHO had approved Oxford–AstraZeneca, Johnson and Johnson, Pfizer–BioNTech, Moderna, Sinopharm BIBP, CoronaVac, Janssen, Covaxin, and Novavax vaccines for emergency use worldwide including low and middle income countries [
7,
8]. The COVID-19 Vaccines Global Access, abbreviated as COVAX, a worldwide initiative aimed at equitable access to COVID-19 vaccines, tests and therapies directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF, provides vaccine to the developing countries [
9,
10].
Like any new vaccine, the anti COVID-19 vaccine acceptance is not shared by all social strata, negatively impacting its implementation. A study on COVID-19 vaccine hesitancy assessment among U.S. medical students conducted on December 26, 2020 has been completed; the majority of participants had positive attitudes towards vaccines and agreed that they would likely be exposed to Covid-19; however, only 53% indicated they would participate in a Covid-19 vaccine trial and 23% were unwilling to take a Covid-19 vaccine immediately [
3]. Another study on vaccine reluctance in faculties of health sciences, dentistry and medicine at the University of Malta vis à vis to flu and the new COVID-19 vaccination on November 12, 2020 was made and revealed that the response rate was 23% (n=852) [
12]. The percentages of those who took the flu shot last year and will take it this year have increased at all ages, highest for medicine and universities; for Covid-19 vaccination, little probable, undecided and likely to take were 30.5/25.3/44.02% respectively. Concerns about the Covid-19 vaccination were related to insufficient knowledge about such a vaccine and potential long-term side effects [
12]. Likewise, a study was conducted on the intention of nurses to accept the 2019 coronavirus disease vaccination and change in intention to accept the seasonal flu vaccination during the Covid-19 pandemic in China on the 21st October 2020. It revealed that most nurses have gone from refusing vaccination to hesitating or accepting than those gone from accepting to hesitating or refusing. 40.0% of participants intended to accept vaccination against Covid-19 and those in the private sector. Reasons for refusing and reluctance to take Covid-19 vaccination included “suspicion about efficacy, efficacy and safety”, “deem it unnecessary” and “no time to take it” [
13]. Globally, few studies have been conducted so far in Africa and in Cameroon, the epidemiological data concerning vaccine acceptance in the general population are scarce. This study aimed to assess the news anti COVID-19 vaccine awareness in the urban and rural areas in Cameroon.
2. Materials and Methods
2.1. Study Design, location, population and period
A cross-sectional, descriptive and analytical study was carried out within a six months’ period, from March 2021 to August 2021. Our sample was constituted essentially of ≥21 years old unvaccinated individuals residing in urban and rural areas, Cameroon.
2.2. Study setting
A cluster sampling at many degrees has been performed by randomly and successfully selecting two mains regions of Cameroon (Littoral and West regions). For that purpose, one populated city (urban area) and village (rural area) were included per region. In the littoral region, Douala (town) and Loum (village) were randomly selected whereas it was Dschang (town) and Mbouda (village) for the west region. In each town/village, streets were first of all randomly selected via pin through on the map, households were then randomly selected via systematic random sampling using dice throw for each street (the number revealed by the dice represented the number of households to jump between included ones) and a single adult or ≥21 years old individual was finally selected via simple random sampling in each household. Participants have been interviewed on their socio-demographic characteristics, knowledge, social behaviors and thoughts relative to Covid-19 disease and vaccine using a structured, pretested and language adapted questionnaire. All questionnaires with lack of information were excluded.
2.3. Data management, ethical considerations
Data were compiled in an excel spreadsheet and analyzed using Epi info 7.0 software (Center for Disease Control and Prevention, USA) and considering a 95% confidence level. Figures were transposed into Excel 2016 spreadsheet. Percentages were compared using the chi-square test and logistic regression bivariate analyzes have been done with a considered margin of error of 5%. Thus, significant associations where considered when the P-value was less than or equal to 0.05.
An ethical approval from the institutional Ethics Committee of the University of Douala (N° 3070CEI-Udo/05/2022/M) and all subsequent administrative authorizations were obtained notably from the sub-divisional officers and Mayors of the concerned towns, and villages. Free and informed consent of respondents were obtained before each interview.
3. Results
3.1. Respondent identification
Throughout this present study, 1056 individuals have been included. However, 3 of them have misfiled the questionnaire and have thus been excluded. Among the 1053 respondents, 611 where residing in urban areas (396 in Douala, and 208 in Dschang) and 442 in rural areas (215 in Loum, and 234 in Mbouda).
Table 1 summarises the distribution of respondents depending on their socio-demographic characteristics.
Table 1 shows that respondents of the group age < 30 years were the most represented 69.52% (732/1053), both in the urban and the rural areas. For the marital status, the sex, the profession, the single, the female sex and the profession with the resourceful ones represented the majority both in the rural and urban areas. In the two areas, the primary level and the Christian community were the greatest in both groups.
3.2. Knowledge of the respondents on Covid-19 and vaccination
Table 2 presents the distribution of respondents according to their knowledge.
Table 2 shows that the majority of respondents in the urban and rural areas knew about the existence of COVID-19 [97.55% (596/611) and 85.07%(376/422) respectively)], the existence of an anti- COVID-19 vaccine [ 97.22%(594/611) and 82.58%(365/422)] respectively) ] and that this vaccine could be effective [68.09%(416/611) and 58.60%(259/442)] respectively)]. Nevertheless, the proportions were significantly higher in urban areas than rural areas. Similarly, the proportion of respondents who knew that we can be infected several times by COVID-19 was significantly greater in urban areas; 82.16% (502/611) than in rural areas;36.65% (162/442).
Table 2 also highlights the fact that, fewer respondents in both urban and rural areas knew neither the highlighted modes of transmission of COVID-19 [31.26% (191/611) and 33.94% (15/442) respectively] nor the symptoms of this disease [4.91% (30/611) and 23.98% (106/442) respectively) and the possibility of recovery from COVID-19 without treatment [38.30% (234/611) and 28.05% (124/442) respectively]. It can be noticed that the percentage of respondents did not know COVID-19 symptoms was significantly lower in urban areas than in rural areas (P<0.0001). Oppositely, the percentage of respondents who knew that there is a possibility of recovery from COVID-19 without treatment was significantly greater in urban areas as compare to rural areas.
3.3. Acceptance of the COVID-19 vaccine by the populations
The distribution of respondents according to their acceptance of the Covid-19 vaccine is summarised in
Table 3.
It appears from
Table 3 that the majority both in the urban and the rural population were neutral for the reception of the COVID-19 vaccine [44.84% (274/611) and 51.58% (228/442) respectively]. Despite the relatively lesser percentage of respondents who agreed to accept anti-COVID-19 vaccine in both areas, it was significantly greater in the urban areas than in the rural areas (P=0.0047). The most frequent reason for reluctance to anti-Covid 19 vaccination was the fact that the vaccine may be not safe due to the speed of synthesis in both urban and rural areas (52.86% and 35.75% respectively). Moreover, the reason based on the fact that the vaccine was to give a disease was significantly more frequent in rural areas (35.07%) than in urban areas (8.84%).
3.4. Determinants of acceptance of vaccination against Covid 19
Table 4 shows the analysis of the probable associated factors to the acceptance of the anti-Covid 19 vaccine in univariate logistic regression.
Overall, it appears from
Table 4 that only the profession (trader) was associated to the acceptance of anti-COVID-19 vaccine acceptance in urban areas (p=0.0046). Meanwhile, both the profession (trader) and the study level (Superior) were statistically associated to vaccine acceptance in rural areas [p<0.0001 and p=0.0001 respectively)
At this purpose, it is observed that the odds of being traders among respondents intending to accept anti-COVID-19 vaccine was respectively 0.54 folds and 0.21 folds the odds of being resourceful in urban and rural areas. Moreover, the odds of being at the superior educational level among respondents ready to accept anti-COVID-19 vaccine was 2.57 folds higher as compare to those with a null educational level.
4. Discussion
In order to contribute in the prevention and the control of the current COVID-19 pandemic and increase the adherence of the population to the vaccination, the present study has been conducted in order to determine the epidemiology of the acceptance of vaccine against Covid-19 in Cameroon urban and rural areas. To carry out this study, we collected data with a structured, pretested and language adapted questionnaire. Our sample were consisted of 1053 individuals. From the applied methodology, it resulted that out of 1053 participants, a preponderance was noted toward females (84.81%), <30years old respondents (69.52%), single respondents (61.73%), resourceful respondents (56.60%), primary level respondents (41.41%), and Christians (93.73%). This globally describes the most frequent socio-demographics in Cameroon.
Globally, the proportion of respondents aware of the existence of COVID-19 pandemic was high in both areas with slightly greater proportion in the urban area [97.55% (596/611) urban and 85.07% (376/422) rural]. This result is close to the one reported in Douala and Bangangté in 2020, where 71.6% declared that COVID-19 existed [
14]. In fact, this is the result of cumulative efforts between WHO, non-government organisations, and governments including wide sensitization and financial support to response against the pandemic spread worldwide [
15]. In addition, as COVID-19 Disease evolved at the time of new technologies, the information about the deadly epidemic rapidly and widely spread through mass media, internet, from school or conferences, person to person.
In this study, 38.65% (407/1053) intended to accept anti-COVID-19 vaccine. This vaccine acceptance rate is relatively lower than that reported by the WHO (72.4%) [
4], and Roman
et al. (44.2%) [
16], Lazarus et al. 79.1% [
17]. Several factors could explain that relative low acceptance rate in our study such as mistrust of government and health authorities, concerns about vaccine safety and efficacy, some obstacles to effective vaccine science communication for lay audiences, public perceptions about that new COVID-19 variants can be possibly less severe, internet driven misinformation and fake news [
18]. Of note, there were still a relative high proportion of the population who did not even believe neither in the existence of COVID-19 7.63%(81/1053) and anti-COVID vaccination 8.9%(94/1053) nor in the effectiveness of that vaccine 35.9%(378/1053). Taken together, all those data strengthen the need of a continuous education and sensitization of the population about the importance and safety of anti-COVID-19 vaccine nationwide.
Nevertheless, the anti-COVID vaccine acceptance rate was greater in urban than in rural area (42.55% vs. 33.26%; p=0.0047). These results are similar to those found in 2022 by Verena Barbieri et al. in Italy [
19]. This similitude can be explained by the fact that reservations regarding COVID-19 vaccination strongly depend on the sociocultural characteristics of the study population. In addition to knowledge about the safety and efficacy of vaccines, fear of side effects, and level of information about the disease and vaccination, religious attitudes may play an important role in rural areas [
20]. Reduced interest in information and a greater lack of trust in institutions and information sources among rural residents were also confirmed.
Upon the answers concerning the reason why they are not accepting the COVID-19 vaccine, the most represented was “the vaccine may not be safe/efficient enough regarding the rapid speed of synthesis and approval for emergence use by WHO”. Many studies, in line with our inquiry, have already incriminated concerns about vaccine safety and efficacy as one of the major reason of vaccine hesitancy [
17,
18,
21]. This can be explained by the fact that, intentional or not, misrepresentation and misinformation can derail progress in COVID-19 vaccination coverage, particularly if audiences choose not to seek COVID-19 information from official sources, such as WHO, the US Centers for Disease Control and Prevention or medical professional associations. These high-credibility sources of information face the additional challenges of pandemic fatigue or distress that may demotivate one to follow recommended protective behaviors and, among some communities, low trust toward such institutions [
22]. In fact, failure to convey clearly and consistently information to lay audiences during the current pandemic may have confused audiences, eroded confidence in the science and reduced vaccine acceptance [
22]. With new technologies, self-digital health literacy through social network, media could have exacerbated this phenomenon [
18].
Upon completion of our study, the acceptance of anti-COVID-19 vaccine was significantly associated to the university level of education (p=0.0001) in the rural area. This is obviously due to the easier aptitude to access good quality information and are hence most aware on correct anti-Covid-19 vaccination issues [
14]. Moreover, trader was the profession with the lowest rate of anti-Covid-19 vaccine acceptance in both urban area and rural area ((p=0.0046 and p<0.0001, respectively). This result indicates the most reluctant socio-professional category to anti-Covid-19 vaccination campaigns. Nevertheless, basic reasons for this reluctance is still unknown, hence suggesting the initiation of researches targeting traders in urban and rural areas in order to better investigate this phenomenon. This can represent an important baseline to mitigate reluctance to anti-Covid-19 vaccination in a general issue.
5. Conclusions
This research shows that knowledge relative to Covid-19 and its vaccine was better in urban areas as compare to rural areas. Also, the acceptance intention was significantly most frequent in urban areas than in rural areas. Moreover, the significant determinants of anti-COVID-19 acceptance were the level of education and profession in the rural areas, and only the profession in the urban areas.
Author Contributions
Conceptualization, Cecile Ingrid Djuikoue; Data curation, Cecile Ingrid Djuikoue; Formal analysis, Cecile Ingrid Djuikoue and Rodrigue Kamga Wouambo; Investigation, Blaise Demanou Fenkeng, Cedric Dylan Seugnou Nana, Joelle Djamfa Nzenya, Flore Fotso Kamgne and Cedric Ngalani Toutchou; Methodology, Cecile Ingrid Djuikoue and Benjamin D. Thumamo Pokam; Project administration, Cecile Ingrid Djuikoue, Majeste Pahane, Benjamin D. Thumamo Pokam and Teke Apalata; Resources, Cecile Ingrid Djuikoue, Blaise Demanou Fenkeng and Teke Apalata; Software, Cecile Ingrid Djuikoue, Cedric Dylan Seugnou Nana and Joelle Djamfa Nzenya; Supervision, Teke Apalata; Validation, Cecile Ingrid Djuikoue, Rodrigue Kamga Wouambo, Cedric Ngalani Toutchou and Teke Apalata; Visualization, Cecile Ingrid Djuikoue, Rodrigue Kamga Wouambo, Majeste Pahane and Flore Fotso Kamgne; Writing—original draft, Cecile Ingrid Djuikoue and Joelle Djamfa Nzenya; Writing—review & editing, Cecile Ingrid Djuikoue, Rodrigue Kamga Wouambo, Majeste Pahane, Blaise Demanou Fenkeng, Cedric Dylan Seugnou Nana, Joelle Djamfa Nzenya, Flore Fotso Kamgne, Cedric Ngalani Toutchou, Benjamin D. Thumamo Pokam and Teke Apalata.
Funding
This research did not receive any specific grant from funding agencies.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Douala University (N° 3070CEI-Udo/05/2022/M).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient(s) to publish this paper.
Data Availability Statement
All data are available upon request.
Acknowledgments
We gratefully thank all participants to this research.
Conflicts of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
- Morens, D.M.; Daszak, P.; Taubenberger, J.K. Escaping Pandora’s box—another novel coronavirus. N Engl J Med 2020, 382, 1293–1295. [Google Scholar] [CrossRef] [PubMed]
- Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020, 395, 507–513. [Google Scholar] [CrossRef] [PubMed]
- Victoria, C.L.; Arati, K.; Nelia, M.A. COVID-19 vaccine hesitancy among medical students. J Public Health (Oxf) 2020. [Google Scholar] [CrossRef]
- WHO. Weekly epidemiological update on COVID-19–30 November 2022, Edition 120, 30 November 2022, Emergency Situational Updates. (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2022, consulted on 05/12/2022 at 19h30).
- WHO Africa, The future of WHO Covid-19 response operations in Africa in 2022. (https://www.afro.who.int/publications/future-who-covid-19-response-operations-africa-2022, consulted on 05/12/2022 at 20h10).
- OMS. Novel Coronavirus (2019-nCoV) Situation Report-11. Avaible online: www.who.int, (accessed on 31 janvier 2020).
- WHO. WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries”. Geneva; 2021. Available online: https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries, (Accessed on 20 January 2023, 19h30).
- Markus, H.; Hannah, K.; Simon, S.; Nadine, K. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280. [Google Scholar] [CrossRef]
- WHO. COVAX-Working for global equitable access to COVID-19 vaccines. Geneva; 2022. Available online: https://www.who.int/initiatives/act-accelerator/covax, (Accessed on 20 January 2023, 19h).
- Yu, Z.; Zixian, Z.; Yujia, W.; Yueqing, Z. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv 2020. [Google Scholar] [CrossRef]
- Silva-Filho, J.; Caruso-Neves, C.; Pinheiro, A. Angiotensin II type-1 receptor (AT1R) regulates expansion, differentiation, and functional capacity of antigen-specific CD8+ T cells. Sci Rep 2016, 6, 35997. [Google Scholar] [CrossRef] [PubMed]
- Grech, V.; Gauci, C. WITHDRAWN: Vaccine hesitancy in the University of Malta Faculties of Health Sciences, Dentistry and Medicine vis-à-vis influenza and novel COVID-19 vaccination. Early Human Development 2020, 105258. [Google Scholar] [CrossRef] [PubMed]
- Wang, K.; Wong, E.; Ho, K.; Cheung, A.; Chan, E.; Yeoh, E.; Wong, S. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey. Vaccine 2020, 38(45), 7049–7056. [Google Scholar] [CrossRef] [PubMed]
- Cécile, D.; Elodie, N.; Gildas, T. Knowledge, Attitudes and Practices of Populations Towards Barrier and Preventive Measures Against COVID-19 in Two Cities in Cameroon. World J Public Health 2021, 6, 89–98. [Google Scholar] [CrossRef]
- Boum, Y.; Fai, K.; Nikolay, B.; Mboringong, A.; Bebell, L.; Ndifon, M.; et al. Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. The Lancet Infectious Diseases 2021, 21(8), 1089–1096. [Google Scholar] [CrossRef] [PubMed]
- Roman, W.; Victor, M.; Corman, W.; Michael, S. Virological assessment of hospitalized patients with COVID-2019. Nature 2020, 581, 465–469. [Google Scholar] [CrossRef]
- Jeffrey, Lazarus; Katarzyna, Wyka; Trenton, White; Camila, Picchio; Lawrence, Gostin; Heidi, Larson; et al. A Survey of COVID-19 Vaccine Acceptance across 23 Countries in 2022. Nature medicine 2023, 23. [Google Scholar] [CrossRef]
- Mohamed-Amine, C.; Diana C., Sanchez-Ramirez; Margriet, P.; Mohy, U.; Caroline, M.; Shabbir, S-A. COVID-19 Infodemic and Digital Health Literacy in Vulnerable Populations: A Scoping Review. Digital Health 2022, 8, 1–13. [Google Scholar] [CrossRef]
- Barbieri, V.; Wiedermann, C.J.; Lombardo, S.; Plagg, B.; Gärtner, T.; Ausserhofer, D.; Wiedermann, W.; Engl, A.; Piccoliori, G. Rural-Urban Disparities in Vaccine Hesitancy among Adults in South Tyrol, Italy. Vaccines 2022, 10, 1870. [Google Scholar] [CrossRef] [PubMed]
- Simanjorang, C.; Pangandaheng, N.; Tinungki, Y.; Medea, G. The determinants of SARS-CoV-2 vaccine hesitancy in a rural area of an Indonesia–Philippines border island: A mixed-method study. Enfermería Clínica (English Edition) 2022, 32(6), 376–384. [Google Scholar] [CrossRef] [PubMed]
- Sharma, R.; Jelly, P.; AS, V.; Chadha, L.; Saxena, V.; Mohan, L. A Comparative Study of Attitudes towards COVID-19 Vaccination in The Rural and Urban Population of Uttarakhand, India. Journal of Global Health Economics and Policy 2021, 1, e2021018. [Google Scholar] [CrossRef]
- Lazarus, J.; Ratzan, S.; Palayew, A.; Gostin, L.; Larson, H.; Rabin, K.; et al. A global survey of potential acceptance of a COVID-19 vaccine. Nature medicine 2021, 27(2), 225–228. [Google Scholar] [CrossRef] [PubMed]
Table 1.
Distribution of respondents according to their socio-demographic characteristics.
Table 1.
Distribution of respondents according to their socio-demographic characteristics.
Variables |
Urban (N=611) |
Rural area (N=442) |
Overall (N=1053) |
|
n (%) |
n (%) |
n (%) |
Age |
|
|
|
[18-30[ |
420 (68.74) |
312 (70.59) |
732 (69.52) |
[30 - 42[ |
121 (19.80) |
89 (20.14) |
210 (19.94) |
>42 |
70 (11.46) |
41 (9.28) |
111 (10.54) |
Marital status |
|
|
|
Single |
373 (61.05) |
277(62.67) |
650 (61.73) |
Divorced/Widow |
12 (1.96) |
3 (0.68) |
15 (1.42) |
Married |
226 (36.99) |
162 (36.65) |
388 (36.85) |
Sex |
|
|
|
Féminin |
519 (84.94) |
374 (84.62) |
893 (84.81) |
Masculin |
92 (15.06) |
68 (15.38) |
160 (15.19) |
Profession |
|
|
|
Trader |
119 (19.48) |
87 (19.68) |
206 (19.56) |
Student |
24 (3.93) |
64 (14.48) |
88 (8.36) |
Resourceful |
384 (62.85) |
212 (47.96) |
596 (56.60) |
Others |
841 (3.75) |
79 (17.87) |
163 (15.48) |
Level of education |
|
|
|
None |
64 (10.47) |
157 (35.52) |
221 (20.99) |
Primary |
271 (44.35) |
165 (37.33) |
436 (41.41) |
Secondary |
99 (16.20) |
36 (8.14) |
135 (12.82) |
Superior |
177 (28.97) |
84 (19.00) |
261 (24.79) |
Religion |
|
|
|
Animist |
2 (0.33) |
2 (0.45) |
4 (0.38) |
Christian |
574 (93.94) |
413 (93.44) |
987 (93.73) |
Muslim |
35 (5.73) |
27 (6.11) |
62 (5.89) |
Table 2.
Distribution of respondents according to their knowledge on the existence and transmission routes of COVID-19.
Table 2.
Distribution of respondents according to their knowledge on the existence and transmission routes of COVID-19.
Variables |
Urban (N=611) |
Rural (N=442) |
P-value |
|
n (%) |
n (%) |
|
COVID-19 exists |
|
|
|
|
No |
15 (2.45) |
66 (14.93) |
|
|
Yes |
596 (97.55) |
376 (85.07) |
<0.0001 |
Modes of transmission |
|
|
|
|
No |
420 (68.74) |
292 (66.06) |
|
|
Yes |
191 (31.26) |
150 (33.94) |
0.3602 |
The symptoms of Covid 19 are: |
|
|
|
|
No |
581 (95.09) |
336 (76.02) |
|
|
Yes |
30 (4.91) |
106 (23.98) |
<0.0001 |
We can recover from COVID-19 without treatment |
|
|
|
|
No |
377 (61.70) |
318 (71.95) |
|
|
Yes |
234 (38.30) |
124 (28.05) |
0.0005 |
We can be infected several times by COVID19 |
|
|
|
|
No |
109 (17.84) |
280 (63.35) |
|
|
Yes |
502 (82.16) |
162 (36.65) |
<0.0001 |
There is a vaccine against COVID-19 |
|
|
|
|
No |
17 (2.78) |
77 (17.42) |
|
|
Yes |
594 (97.22) |
365 (82.58) |
<0.0001 |
Anti Covid Vaccination can be effective |
|
|
|
|
No |
195 (31.91) |
183 (41.40) |
|
|
Yes |
416 (68.09) |
259 (58.60) |
0.0016 |
Table 3.
Distribution of the respondents according of anti-COVID-19 vaccine.
Table 3.
Distribution of the respondents according of anti-COVID-19 vaccine.
Variables |
Urban (N=611) |
Rural (N=442) |
P-value |
|
n (%) |
n (%) |
|
Would you agree to receive COVID-19 vaccine? |
|
|
|
|
Neutral |
274 (44.84) |
228 (51.58) |
Ref |
|
Agree |
260 (42.55) |
147 (33.26) |
0.0047 |
|
Disagree |
77 (12.60) |
67 (15.16) |
0.8137 |
Reasons for not accepting the Covid-19 vaccine |
|
|
|
|
It is a negligible threat disease and can be cured |
48 (7.86) |
27 (6.11) |
Ref |
|
I don’t have enough information about the vaccine |
186 (30.44) |
102 (23.08) |
0.9251 |
|
It is to give us a disease |
54 (8.84) |
155 (35.07) |
<0.0001 |
|
The vaccine may be not safe due to the speed of synthesis |
323 (52.86) |
158 (35.75) |
0.5902 |
Table 4.
Factors to acceptance of the vaccine against Covid-19 in a univariate logistic regression.
Table 4.
Factors to acceptance of the vaccine against Covid-19 in a univariate logistic regression.
Variables |
Vaccine acceptance (Urban area) |
Vaccine acceptance (Rural area) |
|
%(n/N) |
P-value, OR (95% CI) |
%(n/N) |
P-value, OR (95% CI) |
Age |
|
|
|
|
[18-30[ |
40.00(168/420) |
Ref |
34.94(109/312) |
Ref |
[30–42[ |
47.11(57/121) |
0.16291, 0.34 (0.89-2.01) |
31.46(28/89) |
0.5422, 0.85 (0.52-1.42) |
> 42 |
50.00(35/70) |
0.11741, 0.50 (0.90-2.49) |
24.39(10/41) |
0.1829, 0.60 (0.28-1.27) |
Marital status |
|
|
|
|
Single |
39.41(147/373) |
Ref |
31.77(88/277) |
Ref |
Married |
44.69(101/226) |
0.2038 1,24 (0.89-1.74) |
36.42(59/162) |
0.3194, 1.23 (0.82-1.85) |
Sex |
|
|
|
|
Féminin |
41.81(217/519) |
Ref |
33.69(126/374) |
Ref |
Masculin |
46.74(43/92) |
0.3788, 1.22 (0.78-1.91) |
30.88(21/68) |
0.6514, 0.88 (0.50-1.54) |
Profession |
|
|
|
|
Resourceful |
47.66(183/384) |
Ref |
38.68(82/212) |
Ref |
Trader |
32.77(39/119) |
0.0046, 0.54 (0.35-0.82) |
11.49(10/87) |
<0.0001, 0.21 (0.10-0.42) |
Student |
41.67(10/24) |
0.5694, 0.78 (0.34-1.81) |
45.31(29/64) |
0.34361,31,752,31 |
Others |
33.33(28/84) |
0.0578, 0.55 (0.33-0.90) |
32.91(26/79) |
0.3657, 0.78 (0.45-1.34) |
Level of education |
|
|
|
|
None |
43.75(28/64) |
Ref |
23.57(37/157) |
Ref |
Primary |
35.06(95/271) |
0.1957, 0.69 (0.40-1.21) |
42.24(73/165) |
0.1522, 1.54 (0.85-2.77) |
Secondary |
46.46(46/99) |
0.73391, 0.12 (0.59-2.10) |
27.78(10/36) |
0.5960, 1.25 (0.55-2.82) |
Superior |
51.41(91/177) |
0.2942, 1.36 (0.77-2.42) |
32.14(27/84) |
0.0001, 2.57 (1.59-4.16) |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).